Raymond James Reiterates Strong Buy Rating on Alnylam Pharmaceuticals (ALNY)

October 23, 2026 12:41 PM EDT Send to a Friend
Raymond James analyst Martin Auster reiterated a Strong Buy rating and $420.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login